Positive benefit-risk ratio of Psoraleae Fructus: Comprehensive safety assessment and osteogenic effects in rats
文献类型：期刊论文
| 作者 | Shi, Zhuo3; Pan, Jin-chao2,3; Ru, Yi3; Shen, Ning-ning3; Liu, Yu-fu3; Zhang, Cheng3; Wu, Xiang-jun3; Li, Fang-yang3; Cui, Jia-lu3; Yang, Chun-qi3 |
| 刊名 | JOURNAL OF ETHNOPHARMACOLOGY
 |
| 出版日期 | 2024-05-23 |
| 卷号 | 326页码:13 |
| 关键词 | Psoraleae fructus Osteogenic effects Toxicology Long-term administration Liver injury |
| ISSN号 | 0378-8741 |
| DOI | 10.1016/j.jep.2024.117967 |
| 通讯作者 | Li, Chuan(chli@simm.ac.cn) ; Wang, Yu-guang(wangyg@bmi.ac.cn) ; Gao, Yue(gaoyue@bmi.ac.cn) |
| 英文摘要 | Ethnopharmacological relevance: Psoraleae Fructus (PF), the dried fruit of Psoralea corylifolia L., is a commonly used traditional medicine that has contributed to the treatment of orthopedic diseases for thousands of years in China. However, recent PF-related liver injury reports have drawn widespread attention regarding its potential hepatotoxicity risks. Aim of the study: This study was aimed to evaluate the long-term efficacy and chronic toxicity of PF using a 26week administration experiment on rats in order to simulate the clinical usage situation. Materials and methods: The PF aqueous extract was consecutively administrated to rats daily at dosages of 0.7, 2.0, and 5.6 g/kg (equivalent to 1-8 times the clinical doses for humans) for as long as 26 weeks. Samples were collected after 13, 26, and 32 weeks (withdrawal for 6 weeks) since the first administration. The chronic toxicity of PF was evaluated by conventional toxicological methods, and the efficacy of PF was evaluated by osteogenic effects in the natural growth process. Results: In our experiments, only the H group (5.6 g/kg) for 26-week PF treatment demonstrated liver or kidney injury, which the injuries were reversible after 6 weeks of withdrawal. Notably, the PF treatment beyond 13 weeks showed significant benefits for bone growth and development in rats, with a higher benefit-risk ratio in female rats. Conclusions: PF displayed a promising benefit-risk ratio in the treatment and prevention of osteoporosis, a disease that lacks effective medicine so far. This is the first study to elucidate the benefit-risk balance associated with clinical dosage and long-term use of PF, thereby providing valuable insights for rational clinical use and risk control of PF. |
| WOS关键词 | POSTMENOPAUSAL OSTEOPOROSIS |
| 资助项目 | Major Program of National Natural Science Foundation of China[82192910] ; Major Program of National Natural Science Foundation of China[82192911] ; Innovation Team and Talents Cultivation Program of National Admin- istration of Traditional Chinese Medicine[ZYYCXTD-D- 202207] ; Innovation Team and Talents Cultivation Program of National Admin- istration of Traditional Chinese Medicine[ZYYCXTD-C-202009] |
| WOS研究方向 | Plant Sciences ; Pharmacology & Pharmacy ; Integrative & Complementary Medicine |
| 语种 | 英语 |
| WOS记录号 | WOS:001210407500001 |
| 出版者 | ELSEVIER IRELAND LTD |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/310882]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Li, Chuan; Wang, Yu-guang; Gao, Yue |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China 2.Beijing Univ Technol, Fac Environm & Life Sci, Beijing 100124, Peoples R China 3.Beijing Inst Radiat Med, Dept Pharmaceut Sci, Taiping Rd 27, Beijing 100850, Peoples R China |
| 推荐引用方式 GB/T 7714 | Shi, Zhuo,Pan, Jin-chao,Ru, Yi,et al. Positive benefit-risk ratio of Psoraleae Fructus: Comprehensive safety assessment and osteogenic effects in rats[J]. JOURNAL OF ETHNOPHARMACOLOGY,2024,326:13. |
| APA | Shi, Zhuo.,Pan, Jin-chao.,Ru, Yi.,Shen, Ning-ning.,Liu, Yu-fu.,...&Gao, Yue.(2024).Positive benefit-risk ratio of Psoraleae Fructus: Comprehensive safety assessment and osteogenic effects in rats.JOURNAL OF ETHNOPHARMACOLOGY,326,13. |
| MLA | Shi, Zhuo,et al."Positive benefit-risk ratio of Psoraleae Fructus: Comprehensive safety assessment and osteogenic effects in rats".JOURNAL OF ETHNOPHARMACOLOGY 326(2024):13. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。